ArticleCurrent microbiology2026
Comparative Genomic Characterization of a Megaplasmid-harboring Multidrug-Resistant Raoultella ornithinolytica from a Septic Diabetic Patient in Uganda.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Raoultella ornithinolytica is an emerging Gram-negative pathogen implicated in nosocomial infections. However, it remains understudied, especially in low-resource regions, including East Africa. Here, we sought to unravel genomic virulence and antimicrobial resistance (AMR) profiles of a strain (RSM7096), isolated from a Ugandan patient with sepsis and diabetes mellitus. We combined antimicrobial susceptibility testing (AST) based on CLSI M100, 2022, with minimum inhibitory concentration (MIC) to determine its susceptibility/resistance to 16 antibiotics. Then we sequenced its genome (Illumina NovaSeq 6000) and performed multiple bioinformatic analyses to establish its clinical relevance. The BD Phoenix™ system classified the isolate as ESBL phenotype (code 1505), consistent with the presence of blaCTX-M-15, blaTEM-1B and blaOXA-1. The isolate was susceptible to imipenem, gentamicin, tigecycline, levofloxacin, and colistin but resistant to 11 antibiotics, including ceftriaxone and piperacillin/tazobactam used for treatment. Using PathogenFinder, the strain was predicted as a human pathogen (97.63% confidence). Virulence profiling revealed siderophore gene clusters for yersiniabactin and enterobactin, as well as capsular (type KL115) and O-antigen (OL2α.3; serotype O2αγ) loci, suggesting potential immune evasion capacity based on genomic predictions. Further, our detailed genomic analysis enabled us to reconstruct a megaplasmid (pRSM7096p5), which harbored 10 AMR genes, including blaCTX-M-15, blaTEM-1B, and blaOXA-1, responsible for the ESBL phenotype. The megaplasmid also harbors multiple mobile genetic elements, including the transposon Tn3 and insertion sequence ISec9 (ISec9), which are associated with high rates of interspecies horizontal antimicrobial resistance gene transfer. Our results demonstrate that Raoultella ornithinolytica poses a significant health risk, especially to patients with comorbidities. We advocated for rigorous surveillance to monitor and mitigate its impact, particularly in low-resource healthcare settings.
Indexed as
Identifiers
41995853What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.